Why Is Eli Lilly Climbing?

In this video, health-care analyst David Williamson discusses Eli Lilly and its surprising accomplishment of hitting a new 52-week high despite poor trial results for Alzheimer's drug solanezumab. What is propelling shares forward? Watch and find out along with David's take on the recent developments.

Profiting from our increasingly global economy can be as easy as investing in your own backyard. Our free report "3 American Companies Set to Dominate the World" shows you how. Click here to get your free copy before it's gone.

Dave Williamson and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Elan and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 14, 2012, at 10:27 AM, GVA1 wrote:

    What is behind the recent rise at LLY? The analyst fails to suggest an answer, only saying why he thinks it should not have happened. Here is my suggestion: investors familiar with this area see encouraging signs, and more importantly, a clear path forward, in the recently reported data. If Lilly conducts a follow up trial properly and confirms what appears to be the case in the early patient subset, and safety remains good, will the FDA be able to keep this out of patients' and doctors' hands? The ugly patent cliff could be turned into a launch ramp, for a cost that is still easily affordable for a company of this size.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2056170, ~/Articles/ArticleHandler.aspx, 10/21/2016 12:50:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,108.94 -53.41 -0.29%
S&P 500 2,137.46 -3.88 -0.18%
NASD 5,248.46 6.63 0.13%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ELN.DL2 $0.00 Down +0.00 +0.00%
Elan CAPS Rating: ***
JNJ $113.48 Down -1.39 -1.21%
Johnson and Johnso… CAPS Rating: ****
LLY $78.50 Down -0.25 -0.31%
Eli Lilly and Co. CAPS Rating: ***
PFE $32.30 Down -0.25 -0.75%
Pfizer CAPS Rating: ****